Stroke Company Acticor Biotech and Mediolanum Announce a Research Collaboration Agreement
Acticor Biotech SAS and Mediolanum farmaceutici S.p.A., today announced that they have entered into a research collaboration agreement for Acticor’s project ACT-017, a humanized antibody Fragment (Fab). Under the terms of the agreement, Mediolanum will co-finance research and development of ACT-017, currently in preclinical development as a potential next generation antithrombotic treatment for acute ischemic stroke.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161114005835/en/
Under the terms of the agreement, Acticor received an undisclosed nonrefundable lump sum payment for the preclinical development of ACT-017 and is eligible for additional payments to launch clinical development phases I and II. Mediolanum will co-own the results of the collaboration and will acquire marketing rights over two main European countries.
“This agreement further confirms Mediolanum’s strong commitment to identify novel treatments for important underserved medical conditions, such as ACT-017” commented its founder and President, Mr. Rinaldo Del Bono.
“We are excited about this great opportunity. ACT-017 has shown great potential in preclinical development and will be a strong addition to our growing pipeline” added Alessandro Del Bono, CEO of Mediolanum.
Acticor Biotech’s CEO Gilles Avenard stated: “This agreement validates and strengthens our development strategy for ACT-017. We have made excellent progress in our development program and are very proud to be partnering with Mediolanum, an important player in the European pharmaceutical industry.”
About Ischemic stroke - http://acticor-biotech.com/en/stroke/
About Acticor Biotech - http://acticor-biotech.com/en/
About ACT-017, the therapeutic candidate - http://acticor-biotech.com/en/technology/
About Mediolanum farmaceutici - http://www.mediolanum-farma.it/en/index.html
Chief Executive Officer
Mediolanum farmaceutici S.p.A
Business Development Manager
Ottavia Landi di Chiavenna
External Relations Director
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
BUSAN-METROPOLITAN-CITY20.9.2018 13:02 | pressemeddelelse
2018 Busan One Asia Festival to Take Place October 20-28
I4MS20.9.2018 12:32 | pressemeddelelse
L4MS Launches Its First Open Call for Cross-Border Application Experiments
CA-UPHOLD20.9.2018 12:02 | pressemeddelelse
Uphold Makes Cred’s LBA Tokens Available For Purchase in 170+ Countries
ANT-FINANCIAL20.9.2018 11:51 | pressemeddelelse
Ant Financial Launches Ant Financial Technology Brand with Full Suite of Technology Products and Services to Support Growth of Financial Institutions
INVENGO20.9.2018 10:02 | pressemeddelelse
Invengo Releases Latest Version of Its ACUITY Digital Platform for Linen Inventory Management
ALIBABA-GROUP-HOLDING20.9.2018 09:19 | pressemeddelelse
Alibaba Announces Smart Mobility Initiatives with Partners
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum